Navigation Links
Assessing lead time of selected ovarian cancer biomarkers
Date:12/30/2009

Concentrations of the biomarkers CA125, human epididymis protein 4 (HE4), and mesothelin began to rise 3 years before clinical diagnosis of ovarian cancer, according to a new study published online December 30 in the Journal of the National Cancer Institute. However, the biomarkers became substantially elevated only in the last year prior to diagnosis. The stage of the cancer at the time of marker elevation is not known.

CA125, HE4, mesothelin, B7-H4, decoy receptor 3, and spondin-2 have been identified as potential ovarian cancer biomarkers, but their behavior in the pre-diagnostic period, with the exception of CA125, has not been evaluated previously.

In this study, Garnet L. Anderson, Ph.D., of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center in Seattle, and colleagues analyzed stored serum samples from the Carotene and Retinol Efficacy Trial, a randomized, double-blind, placebo-controlled chemoprevention trial testing the effects of beta-carotene and retinol on lung cancer incidence among individuals at high risk for the disease. The researchers identified 34 patients who were diagnosed with ovarian cancer and had serum specimens available from the trial, as well as 70 matched control subjects.

Serum concentrations of CA125, HE4, and mesothelin began to increase slightly in cancer patients approximately 3 years before diagnosis but became substantially elevated only about a year before diagnosis.

These data suggest the presence of ovarian cancer up to 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year, according to the authors.

"Although these markers are not accurate enough to prompt early intervention in existing screening protocols, the multivariable regression analyses identified modest but statistically significant increases in risk associated with CA125, HE4, and mesothelin, which are consistent with many of the established epidemiological risk factors for ovarian cancer," the authors write.

In an accompanying editorial, Patricia Hartge, ScD, of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., applauds the authors for taking the field one step closer to successful screening designs by showing that the levels of certain biomarkers do not increase early enough to be used for screening.

"The results of Anderson et al. are not the last word in serum markers or in combinations of markers," the editorialist writes. "Serum markers likely will form a key element in any screening regimen, with the lead time and other parameters of each marker or combination of markers being taken into account. The careful evaluation technique applied in the current study fits into a staged approach necessary for testing performance of early markers of disease."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related biology news :

1. Breakthrough made in assessing marine phytoplankton health
2. Lighting research center develops framework for assessing light pollution
3. Research identifies first method for testing, assessing drug treatments for Chagas disease
4. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
5. BIO-key(R) Selected as 2009 Industry Innovator in Biometrics by SC Magazine
6. Ph.D. student in K-State plant pathology selected for international fellowship
7. ComCam Selected by ePortation on New Maritime Domain Awareness Project
8. M2SYS Biometric Software Solution Selected By GHG Corporation
9. UC Riverside student is 1 of only 5 persons selected for challenging Arctic expedition
10. ComCam Selected by ePortation on New Maritime Domain Awareness Project
11. Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... ... May 23, 2017 , ... Customers ... their control technology again and again. METTLER TOLEDO has released two new videos ... videos illustrate how integration of the ACT350 into Siemens and Allen Bradley PLCs ...
(Date:5/22/2017)... ... 2017 , ... Cancer diagnostics and pathology workflow solution provider ... Association for Pathology Informatics Annual Summit at the Wyndham Grand Hotel ... Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to help ...
(Date:5/19/2017)... ... May 19, 2017 , ... In response to the strong base of evidence ... Inc. announces the release of their Gait Trainer 3 with an Integrated Music Therapy ... system to aid in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added another option ... two-hour team-building package designed for groups of 10-30 people. Guests can choose ... items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with Pepperoni and ...
Breaking Biology Technology: